Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG.

Respir Med. 2018 Jan;134:143-149. doi: 10.1016/j.rmed.2017.12.006. Epub 2017 Dec 13.


Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.

Zhu R, Zheng Y, Dirks NL, Vadhavkar S, Jin JY, Peng K, Holweg CTJ, Olsson J, Matthews JG, Putnam WS.

Pulm Pharmacol Ther. 2017 Oct;46:88-98. doi: 10.1016/j.pupt.2017.08.010. Epub 2017 Aug 24.


A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers.

Pan L, Belloni P, Ding HT, Wang J, Rubino CM, Putnam WS.

Adv Ther. 2017 Sep;34(9):2071-2082. doi: 10.1007/s12325-017-0594-8. Epub 2017 Aug 14.


Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.

Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.


Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.

Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.


Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.

Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM.

Sci Transl Med. 2014 Jul 2;6(243):243ra85. doi: 10.1126/scitranslmed.3008961.


The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.

Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.


Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies.

Mortensen DL, Prabhu S, Stefanich EG, Kadkhodayan-Fischer S, Gelzleichter TR, Baker D, Jiang J, Wallace K, Iyer S, Fielder PJ, Putnam WS.

MAbs. 2012 Nov-Dec;4(6):724-31. doi: 10.4161/mabs.22216.


Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.

J Allergy Clin Immunol. 2013 Sep;132(3):567-574.e12. doi: 10.1016/j.jaci.2013.03.051. Epub 2013 May 29.


Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.

AAPS J. 2013 Apr;15(2):559-70. doi: 10.1208/s12248-013-9463-9. Epub 2013 Feb 15.


Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.

Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF.

MAbs. 2012 Mar-Apr;4(2):243-55. doi: 10.4161/mabs.4.2.19387. Epub 2012 Mar 1.


Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.

Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM.

Trends Biotechnol. 2010 Oct;28(10):509-16. doi: 10.1016/j.tibtech.2010.07.001. Epub 2010 Aug 4. Review.


Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.

Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, Deniz Y, Lowman H, Fielder P, Visich J, Joshi A, Jumbe NS.

AAPS J. 2008 Jun;10(2):425-30. doi: 10.1208/s12248-008-9045-4. Epub 2008 Aug 7. Review.


Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics.

Putnam WS, Woo JM, Huang Y, Benet LZ.

J Clin Pharmacol. 2005 Apr;45(4):411-21.


Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transporters.

Putnam WS, Pan L, Tsutsui K, Takahashi L, Benet LZ.

Pharm Res. 2002 Jan;19(1):27-33.


Pseudo-migration of a biliary stent.

Affronti J, Branch MS, Putnam WS, Baillie J.

Gastrointest Endosc. 1991 Jul-Aug;37(4):497-8. No abstract available.


Endoscopic laser lithotripsy of large bile duct stones.

Cotton PB, Kozarek RA, Schapiro RH, Nishioka NS, Kelsey PB, Ball TJ, Putnam WS, Barkun A, Weinerth J.

Gastroenterology. 1990 Oct;99(4):1128-33.


Inhibitory regulation of rat exocrine pancreas by peptide YY and pancreatic polypeptide.

Putnam WS, Liddle RA, Williams JA.

Am J Physiol. 1989 Apr;256(4 Pt 1):G698-703.


The hepatic extraction of gastric inhibitory polypeptide and insulin.

Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS.

Endocrinology. 1984 Sep;115(3):1011-8.


Selective potentiation of insulin-mediated glucose disposal in normal dogs by the sulfonylurea glipizide.

Putnam WS, Andersen DK, Jones RS, Lebovitz HE.

J Clin Invest. 1981 Apr;67(4):1016-23.


Weight No Advantage in Artificial Lower Dentures.

Putnam WS.

Am J Dent Sci. 1858 Jul;8(3):337-339. No abstract available.

Supplemental Content

Loading ...
Support Center